|Bid||226.30 x 800|
|Ask||0.00 x 900|
|Day's Range||224.52 - 226.85|
|52 Week Range||95.58 - 257.88|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||37.74|
|Earnings Date||Feb 09, 2021 - Feb 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||261.38|
Moody's Investors Service ("Moody's") upgraded the ratings of Charles River Laboratories International, Inc. including the Corporate Family Rating to Ba1 from Ba2 and the Probability of Default Rating to Ba1-PD from Ba2-PD. There is no change to Charles River's SGL-1 Speculative Grade Liquidity Rating. "The ratings upgrade reflects our recognition of Charles River's improved credit profile and strong revenue growth outlook for the next several years," said Moody's Vice President, Morris Borenstein.
Charles River (CRL) possesses solid growth attributes, which could help it handily outperform the market.
PathoQuest establishes U.S. subsidiary with state-of-the-art biologics genomic testing laboratory at Charles River’s site in Wayne, PA.